Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Report includes call to action outlining steps Congress must take to maintain momentum.
The new bispecific T-cell engager is approved for people who have received at least four prior lines of treatment.
Talquetamab is indicated for patients who have tried at least four prior lines of treatment.
More than 40% of patients treated with the bispecific T-cell engager experienced complete remission.
This is the first investigational therapy in a Phase III trial to improve overall survival in uveal melanoma,” a cancer of the eye.
Kimmtrak, a novel bispecific T-cell engager, improved overall survival in a clinical trial.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.